Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, phase I clinical trial aimed to evaluate the efficacy
and safety of Osimertinib+Bevacizumab+Carboplatin and Pemetrexed for Untreated Patients With
EGFR Mutation Advanced Non-squamous Non-Small Cell Lung Cancer With Concomitant Mutations.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital